Key Differences Between Atrasentan and Ambrisentan

Atrasentan (atrasentan) and ambrisentan (Ambrisentan) are both endothelin receptor antagonists (Endothelin Receptor Antagonists, ERAs). They are similar in molecular structure and target, but there are significant differences in their clinical uses, pharmacological characteristics and metabolic pathways. Atrasentan is a highly selective endothelin A receptor (ETA) antagonist, mainly used in the treatment of primary immunoglobulin A nephropathy. Its core mechanism is to inhibit endothelin-1-mediated renal vasoconstriction and inflammatory response, thereby reducing proteinuria and delaying the decline of renal function. Ambrisentan is widely used to treat pulmonary arterial hypertension (PAH). It dilates pulmonary arteries, reduces pulmonary vascular resistance, and improves right heart function and exercise tolerance. It is currently one of the mainstream drugs for the treatment of pulmonary arterial hypertension in the world.

From the perspective of pharmacological effects, atrasentan mainly focuses on regulating renal microcirculation. By inhibitingETA receptor activity, it reduces glomerular capillary pressure and reduces the expression of fibrosis factors, thereby delaying diabetic kidney damage. Its ETA selectivity is higher than that of ambrisentan, and the antagonistic ratio of ETA to ETB receptors is about 1200:1. Therefore, it can achieve a strong renal protective effect at a lower dose, while reducing interference with ETB receptors and avoiding side effects such as sodium retention caused by ETB blockade. Relatively speaking, although ambrisentan is also an ETA selective antagonist, its selectivity is slightly lower and it is more suitable for vasoconstriction-related diseases such as pulmonary hypertension. It can effectively dilate blood vessels in the lungs and improve blood oxygenation, but it has been less studied in kidney disease, and long-term use requires close monitoring of liver function.

The difference between the two is particularly prominent in terms of indications. Atrasentan is clinically positioned in the field of chronic kidney disease, especially for patients with type 2 diabetes and proteinuria. Its long-term treatment goal is to delay the decline of renal function and reduce the risk of dialysis or kidney transplantation. Ambrisentan focuses on improving the cardiopulmonary function of patients with pulmonary hypertension and is used to relieve symptoms such as shortness of breath and fatigue. The therapeutic endpoints of the two drugs are different. Atrasentan mainly focuses on renal function protection and reduction of urinary protein, while the clinical endpoint of ambrisentan is improvement of exercise distance and hemodynamics.

In terms of metabolism and pharmacokinetics, atrasentan is mainly metabolized by the liverCYP3A enzyme system and has a long half-life. Generally, oral administration once a day can maintain stable blood concentration. Ambrisentan is also metabolized by the liver, but has a larger volume of distribution and a higher plasma protein binding rate, which allows it to have a more sustained vasodilatory effect in the treatment of vascular diseases. There are also differences in drug interactions between the two. When atrasentan is used in combination with diuretics or ACEI drugs, caution must be taken to prevent sodium and water retention, while ambrisentan is more concerned about the interaction with cyclosporine drugs.

In terms of price, since atrasentan is a new generation of kidney disease treatment drugs, the current overseas price is relatively high.The price of 0.75mg × 30 tablets is about US$13,000, and there are currently no generic drugs. Ambrisentan has been on the market for many years, and there are many imitation versions in the world. Its price is relatively more affordable, generally ranging from hundreds to thousands of yuan. Domestically, although atrasentan has been approved, it has not yet been officially sold, while ambrisentan has long been on the market in China and has been included in medical insurance.

Reference materials:https://www.vanrafia.com/